Evidence map›Paper›PMID 42231029›Full record

ArticleBritish journal of cancer2026

Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma.

Xiaoxuan Li, Tobias Janik, Markus Möbs, Stefan Florian, Wolfgang D Schmitt, Amra Dzakulic, Jalid Sehouli, David Horst, Frank P B Dubois, Elena Ioana Braicu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoxuan LiCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany.
Tobias JanikCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany.
Markus MöbsCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany.
Stefan FlorianCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany.
Wolfgang D SchmittCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany.ORCID http://orcid.org/0000-0002-7870-138X
Amra DzakulicCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow Klinikum, Berlin, Germany.
Jalid SehouliCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow Klinikum, Berlin, Germany.
David HorstCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany.ORCID http://orcid.org/0000-0003-4755-5743
Frank P B DuboisCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany. frank.dubois@charite.de.ORCID http://orcid.org/0000-0002-7654-6208
Elena Ioana BraicuCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow Klinikum, Berlin, Germany. elena.braicu@charite.de.ORCID http://orcid.org/0000-0001-5357-6001
Mihnea P DragomirCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany. mihnea.dragomir@charite.de.ORCID http://orcid.org/0000-0002-5550-3516

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibody-drug conjugates (ADCs) represent a promising therapeutic approach for high-grade serous ovarian carcinoma (HGSOC). Patient selection for ADC therapy depends on tumour target expression, making it essential to characterize molecular, spatial, and temporal heterogeneity.

methodsWe analyzed two HGSOC tissue microarray cohorts: 100 genomically profiled cases (1565 cores) and 64 matched cases with paired adnexal (A), locally advanced (LA), and recurrent (R) samples (2395 cores). Associations between ADC target expression and molecular characteristics, sampling site, and survival were investigated.

resultsADC targets showed no significant associations with homologous recombination deficiency (HRD) or TP53 mutation status; TROP2 was modestly lower in BRCA1/2-mutated tumours. Folate receptor-alpha (FolR1) showed notable spatial heterogeneity: 20.2% switched therapeutic-indication groups between centre and margin at A; 21.7% were reclassified between A and LA. Temporally, all markers showed ≥ 20% switching, reaching 38.4% for FolR1 between A and R. High FolR1 expression in A correlated with poorer survival, a pattern not observed in LA or R samples.

conclusionsADC targets in HGSOC display limited molecular but significant spatial and temporal heterogeneity, with expression classifications varying by site and time. FolR1 expression in adnexal tumours associates with aggressive disease.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsAgedAntigens, NeoplasmBiomarkers, TumorBRCA1 ProteinCell Adhesion MoleculesFemaleFolate Receptor 1HumansMiddle AgedMutationNeoplasm GradingTumor Suppressor Protein p53Antigens, NeoplasmBiomarkers, TumorBRCA1 ProteinCell Adhesion MoleculesFolate Receptor 1FOLR1 protein, humanTACSTD2 protein, humanTumor Suppressor Protein p53

Identifiers

PMID42231029
PMCPMC13478159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.